Treating your Eyes
Treating your eyes
Cross-Linking: Off-label applications Epi-off CXL Cross-linking the cornea isn’t without drawbacks. Thanks to the need to remove the central 9 mm of corneal epithelial cells before riboflavin instillation, the standard, ...
Awards and Distinctions
Our research laboratory at the University of Zurich
The ELZA co-founder Prof. Farhad Hafezi is running a research laboratory at the University of Zurich, Switzerland. The main foci are corneal biomechanics (keratoconus) and ocular cell biology.
Visit the CABMM’s website here.
We proudly announce that the second edition of our medical textbook “Corneal Cross-Linking” will soon appear with Slack Inc. The book is edited by ELZA Founder Farhad Hafezi (University of Geneva & USC Los Angeles) and J. Bradley Randleman (USC Los Angeles). It is the oldest and most complete international textbook on cross-linking technology.
Our International humanitarian initiative
To increase awareness about keratoconus in children.
To disseminate information amongst parents and children.
To treat children with keratoconus in National Reference Sites.
To perform research to identify the causes of keratoconus.
Visit the Light for Sight website here.
ELZA in the global „Top 40 under 40“
We are proud to announce that our co-founder and head of Strategy and BD&L, Nikki Hafezi, MASIP ETHZ, was voted by her peers among the Top 40 under 40 in the British journal „The Ophthalmologist. This list comprises „the most important upcoming personalities in global opthalmology„.
Mrs Hafezi also serves as CEO of EMAGine SA.
Developing the future of Cross-Linking Technology
ELZA members co-founded a Spin-Off Company: EMAGine SA.
EMAGine SA develops a cross-linking device that will fit on a slit lamp.
The device will allow for treatment outside an operating theatre.
Visit EMAGine’s website here.